Correction: Real‑world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first‑ or second‑line treatment for hormone receptor-positive, HER2‑negative advanced or metastatic breast cancer

Tetsuhiro Yoshinami¹, Yuko Takano², Yukinori Ozaki³, Yukiko Kajiwara⁴, Mitsugu Yamamoto⁵, Ken-Ichi Watanabe⁵, Masami Tsukabe⁶, Fumie Fujisawa⁷, Shigenori E Nagai⁸, Nobuhiro Shibata⁹, Chiya Oshiro¹⁰, Hiroko Bando¹¹, Nobuyuki Tsunoda¹², Kazuhiko Yamagami¹³, Kei Koizumi¹⁴, Masahiro Takada¹⁵, Naoko Toriguchi¹⁶, Nobuyuki Sekine¹⁶, Tsutomu Kawaguchi¹⁶, Shigehira Saji¹⁷, Yasuaki Sagara¹⁸, Satoshi Morita¹⁹, Norikazu Masuda²⁰

Affiliations

¹ Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, 2-2-E10 Yamadaoka, Suita, Osaka, 565-0871, Japan. yosinami-te@onsurg.med.osaka-u.ac.jp.
² Department of Breast and Endocrine Surgery, Nagoya University Hospital, Nagoya, Aichi, Japan.
³ Department of Breast Medical Oncology, The Cancer Institute Hospital of JFCR, Tokyo, Japan.
⁴ Department of Breast Surgery, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.
⁵ Department of Breast Oncology, National Hospital Organization Hokkaido Cancer Center, Sapporo, Hokkaido, Japan.
⁶ Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, 2-2-E10 Yamadaoka, Suita, Osaka, 565-0871, Japan.
⁷ Department of Medical Oncology, Shiga General Hospital, Moriyama, Shiga, Japan.
⁸ Division of Breast Oncology, Saitama Cancer Center, Kitaadachi-gun, Saitama, Japan.
⁹ Department of Clinical Oncology, Kansai Medical University Hospital, Hirakata, Osaka, Japan.
¹⁰ Department of Breast Surgery, Kaizuka City Hospital, Kaizuka, Osaka, Japan.
¹¹ Department of Breast and Endocrine Surgery, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.
¹² Department of Breast Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Nagoya, Aichi, Japan.
¹³ Department of Breast Surgery and Oncology, Shinko Hospital, Kobe, Hyogo, Japan.
¹⁴ Department of Surgery 1, Division of Breast Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
¹⁵ Department of Breast Surgery, Kansai Medical University, Hirakata, Osaka, Japan.
¹⁶ Department of Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K, Kobe, Hyogo, Japan.
¹⁷ Department of Medical Oncology, Fukushima Medical University, Fukushima, Japan.
¹⁸ Department of Breast and Thyroid Surgical Oncology, Social Medical Corporation Hakuaikai Sagara Hospital, Kagoshima, Japan.
¹⁹ Department of Biomedical Statistics and Bioinformatics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
²⁰ Department of Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

PMID: 40549070
PMCID: PMC12394238
DOI: 10.1007/s12282-025-01736-0

Published Erratum

Correction: Real‑world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first‑ or second‑line treatment for hormone receptor-positive, HER2‑negative advanced or metastatic breast cancer

Tetsuhiro Yoshinami et al. Breast Cancer. 2025 Sep.

. 2025 Sep;32(5):1157-1158.

doi: 10.1007/s12282-025-01736-0.

Authors

Affiliations

¹ Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, 2-2-E10 Yamadaoka, Suita, Osaka, 565-0871, Japan. yosinami-te@onsurg.med.osaka-u.ac.jp.
² Department of Breast and Endocrine Surgery, Nagoya University Hospital, Nagoya, Aichi, Japan.
³ Department of Breast Medical Oncology, The Cancer Institute Hospital of JFCR, Tokyo, Japan.
⁴ Department of Breast Surgery, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.
⁵ Department of Breast Oncology, National Hospital Organization Hokkaido Cancer Center, Sapporo, Hokkaido, Japan.
⁶ Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, 2-2-E10 Yamadaoka, Suita, Osaka, 565-0871, Japan.
⁷ Department of Medical Oncology, Shiga General Hospital, Moriyama, Shiga, Japan.
⁸ Division of Breast Oncology, Saitama Cancer Center, Kitaadachi-gun, Saitama, Japan.
⁹ Department of Clinical Oncology, Kansai Medical University Hospital, Hirakata, Osaka, Japan.
¹⁰ Department of Breast Surgery, Kaizuka City Hospital, Kaizuka, Osaka, Japan.
¹¹ Department of Breast and Endocrine Surgery, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.
¹² Department of Breast Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Nagoya, Aichi, Japan.
¹³ Department of Breast Surgery and Oncology, Shinko Hospital, Kobe, Hyogo, Japan.
¹⁴ Department of Surgery 1, Division of Breast Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
¹⁵ Department of Breast Surgery, Kansai Medical University, Hirakata, Osaka, Japan.
¹⁶ Department of Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K, Kobe, Hyogo, Japan.
¹⁷ Department of Medical Oncology, Fukushima Medical University, Fukushima, Japan.
¹⁸ Department of Breast and Thyroid Surgical Oncology, Social Medical Corporation Hakuaikai Sagara Hospital, Kagoshima, Japan.
¹⁹ Department of Biomedical Statistics and Bioinformatics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
²⁰ Department of Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

PMID: 40549070
PMCID: PMC12394238
DOI: 10.1007/s12282-025-01736-0

No abstract available

PubMed Disclaimer

Erratum for

Real-world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first- or second-line treatment for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.
Yoshinami T, Takano Y, Ozaki Y, Kajiwara Y, Yamamoto M, Watanabe KI, Tsukabe M, Fujisawa F, Nagai SE, Shibata N, Oshiro C, Bando H, Tsunoda N, Yamagami K, Koizumi K, Takada M, Toriguchi N, Sekine N, Kawaguchi T, Saji S, Sagara Y, Morita S, Masuda N. Yoshinami T, et al. Breast Cancer. 2025 Jul;32(4):841-856. doi: 10.1007/s12282-025-01713-7. Epub 2025 May 20. Breast Cancer. 2025. PMID: 40392524 Free PMC article.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- PubMed Central
- Springer
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Correction: Real‑world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first‑ or second‑line treatment for hormone receptor-positive, HER2‑negative advanced or metastatic breast cancer

Affiliations

Correction: Real‑world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first‑ or second‑line treatment for hormone receptor-positive, HER2‑negative advanced or metastatic breast cancer

Authors

Affiliations

Erratum for

Publication types

LinkOut - more resources

Full Text Sources

Research Materials

Miscellaneous